Medical Statistics has never been easier!

David E. Matthews
Vernon T. Farewell

Using and Understanding Medical Statistics
5th, revised and extended edition

The fifth revised edition of this highly successful book presents the most extensive enhancement since Using and Understanding Medical Statistics was first published 30 years ago. Without question, the single greatest change has been the inclusion of source code, together with selected output, for the award-winning, open-source, statistical package known as R. This innovation has enabled the authors to de-emphasize formulae and calculations, and let software do all of the 'heavy lifting'.

This edition also introduces readers to several graphical statistical tools, such as Q-Q plots to check normality, residual plots for multiple regression models, funnel plots to detect publication bias in a meta-analysis and Bland-Altman plots for assessing agreement in clinical measurements. New examples that better serve the expository goals have been added to a half-dozen chapters. In addition, there are new sections describing exact confidence bands for the Kaplan-Meier estimator, as well as negative binomial and zero-inflated Poisson regression models for over-dispersed count data.

The end result is not only an excellent introduction to medical statistics, but also an invaluable reference for every discerning reader of medical research literature.

Contents
Preface to the Fifth Edition
Prefaces to the Previous Editions

- Basic Concepts
- Tests of Significance
- Fisher’s Test for $2 \times 2$ Contingency Tables
- Approximate Significance Tests for Contingency Tables
- Some Warnings concerning $2 \times 2$ Tables
- Kaplan-Meier or ‘Actuarial’ Survival Curves
- The Log-Rank or Mantel-Haenszel Test for Comparing Survival Curves
- An Introduction to the Normal Distribution
- Analyzing Normally Distributed Data
- Linear Regression Models for Medical Data
- Binary Logistic Regression
- Regression Models for Count Data
- Proportional Hazards Regression
- The Analysis of Longitudinal Data
- Analysis of Variance
- Data Analysis
- The Question of Sample Size
- The Design of Clinical Trials
- Further Comments regarding Clinical Trials
- Meta-Analysis
- Epidemiological Applications
- Diagnostic Tests
- Agreement and Reliability

References
Subject Index

Matthews, D.E. (Waterloo, Ont.); Farewell, V.T. (Cambridge)
Using and Understanding Medical Statistics
5th, revised and extended edition
XX + 338 p., 48 fig., 103 tab., 2015
CHF 49.00 / EUR 46.00 / USD 54.00
(hard cover + online supplementary material)
Online version for institutional purchase
Prices subject to change, VAT not included
EUR price for eurozone countries, USD price for USA and Latin America only
(hard cover + online supplementary material)

Dear Librarian
I have reviewed this publication and would like to recommend it for our library
Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, F +41 61 306 12 34
www.karger.com
Submission
Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author’s original (handwritten) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion scientist(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.

Presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals [see International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (April 2010 version). Available from: http://www.ICMJE.org].

In case of problems with submission, please contact: che@karger.com.

S. Karger AG – Medical and Scientific Publishers
Editorial Office ‘Chemotherapy’
Allschwilerstrasse 10
CH – 4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions
All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approve the manuscript submission. Submission of an article for publication implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of Chemotherapy and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest
Authors are required to disclose any sponsorship or funding arrangements related to the research presented in the manuscript and any possible conflicts of interest. A possible conflict of interest does not preclude consideration of a manuscript for publication, but the Editor might consider it appropriate to publish the disclosed information with the paper. All forms of support and financial involvement should be listed in the Acknowledgements section of the paper. The cover letter should certify that all forms of conflict of interest by all authors were clearly identified in the text.

Ethics
Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the Declaration of Helsinki (World Medical Association; http://www.wma.net/en/30publications/10policies/b3/index.html). In particular, authors should state in the Materials and Methods section that subjects have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. Authors should also state that animal experimentation was approved by an independent ethics committee. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. Karger Publishers defines plagiarism as reproduction of another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Sections
Authors should indicate in the cover letter which manuscript type is being submitted for publication:

Original Papers: Fully documented reports of original research that must describe full sets of significant, original experiments in current anti-infective and antitumor chemotherapy research. Abstract, Introduction, Materials and Methods, Results, and Discussion sections are included. Consideration for publication is based on originality, novelty, scientific soundness, and appropriate analysis (maximum 3,000 words, 80 references, plus tables/figures).

Reviews: Comprehensive, state-of-the-art papers covering a timely topic by experts in the field (maximum 4,000 words, plus tables/figures, references). Reviews are usually invited by the Editor but may be unsolicited. Authors are asked to contact the Editor-in-Chief before submission in order to avoid clashes with other pending reviews. All review papers are subject to peer review. An unstructured abstract of no more than 200 words is required.

Novel Insights from Clinical Practice: The journal only considers case reports that provide significant new insights into a clinical problem or with an extremely unusual clinical course. Submissions can be based around a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. The manuscript should contain an unstructured abstract (maximum 150 words), introduction, case report and discussion section (maximum 2,000 words, maximum 2 tables or figures). Boxes containing bulleted points on established facts (what is already known) and Novel Insights (new information gained) are required on the first page of the report. These should highlight the novelty of the clinical observation.

Short Communications: Short reports, brief laboratory observations, and preliminary communications can be submitted for accelerated publication under Short Communications. They must present new findings of sufficient importance to justify their accelerated acceptance. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts (maximum 1,600 words).

Letters to the Editor: Letters to the Editor are encouraged if they directly concern articles recently published in this journal. If accepted, the Editor reserves the right to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Editor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement
The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: The first page should contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc. where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/Aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lower-case) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ® or ™ when they are first mentioned.

Tables and illustrations: Tables and figures must be numbered (e.g. Figure 1, Figure 2) and submitted as separate files. Tables require a heading and a figure, a legend, which must provide sufficient information for either to stand alone. Each figure and table must be cited in the text numerically. Tables should be in Word format. b/w half-tone and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PSD, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.
Contents

See the journal website for contents
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.

Oncology
International Journal of Cancer Research and Treatment

Editor-in-Chief
M. Markman,

Associate Editor
P. Dufour,
Strasbourg

Regional Editor Japan
O. Hino,
Tokyo

Selected contributions
• Adherence and Patients’ Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies: Barthélémy, P.; Asmani-De la Porte, I.; Meyer, N.; Duclos, B.; Serra, S.; Dourthe, L.-M.; Amé, S. (Strasbourg); Littique, V.; Giron, C.; Goldberg, V.; Forrecker, L.; Quoix, E.; Kurtz, J.-E. (Strasbourg)
• Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer: Park, J.S.; Rha, S.Y.; Chung, H.C.; Jung, M. (Seoul); Kim, K.H. (Busan); An, J.Y.; Kim, H.-I.; Cheong, J.-H.; Hyung, W.J.; Noh, S.H.; Kim, H.S. (Seoul)
• The Evolving Use of Radioiodine Therapy in Differentiated Thyroid Cancer: Mayson, S.E.; Yoo, D.C.; Gopalakrishnan, G. (Providence, R.I.)
• Hereditary Cancer-Associated Mutations in Women Diagnosed with Two Primary Cancers: An Opportunity to Identify Hereditary Cancer Syndromes after the First Cancer Diagnosis: Saam, J.; Meyes, K.; Landon, M.; Williams, K.; Kaldate, R.R.; Arnell, C.; Wenstrup, R. (Salt Lake City, Utah)
• The Impact of Symptom Burden on Patient Quality of Life in Chronic Myeloid Leukemia: Cella, D.; Nowinski, C.J.; Frankfurt, O. (Chicago, Ill.)
• FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer: Chaix, M.; Nowinski, C.J.; Lorgis, V.; Ghiiringhelli, F. (Dijon)
• Treatment of Brain Metastases: Lukas, R.V. (Chicago, Ill.); Gablikian, P. (Los Angeles, Calif.); Garza, M.; Chmura, S.J. (Chicago, Ill.)

More information at www.karger.com/ocl
1 Editorial
Minotti, G.; Graziani, G.; Delogu, G. (Rome)

Antimicrobial Section

Original Papers

3 Safety and Outcome of Pharmacy-Led Vancomycin Dosing and Monitoring
Momattin, H.; Zogheib, M.; Homoud, A. (Dhahran); Al-Tawfiq, J.A. (Dhahran/Indianapolis, Ind.)

8 Biofilm Formation and Susceptibility to Polymyxin B by a Highly Prevalent Clone of Multidrug-Resistant Acinetobacter baumannii from a Mexican Tertiary Care Hospital
Rosales-Reyes, R.; Alcántar-Curiel, M.D.; Jarillo-Quijada, M.D.; Gayosso-Vázquez, C. (Mexico City); Morfin-Otero, M.d.R.; Rodríguez-Noriega, E. (Guadalajara); Santos-Preciado, J.I. (Mexico City)

Anticancer Section

Original Papers

15 A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study
Selle, F. (Paris); Pautier, P.; Lhomme, C. (Villejuif); Viens, P. (Marseille); Fabbro, M. (Montpellier); Lokiec, F. (Saint-Cloud); Gligorov, J.; Richard, S.; Provent, S.; Soares, D.G.; Lotz, J.-P. (Paris)

23 Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer

32 Fabrication of Alginate/Calcium Carbonate Hybrid Microparticles for Synergistic Drug Delivery
Peng, Y.; Sun, H.-Y.; Wang, Z.-C.; Xu, X.-D.; Song, J.-C.; Gong, Z.-J. (Wuhan)

41 Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis

51 Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer
Azadeh, P.; Mortazavi, N.; Tahmasebi, A. (Tehran); Hosseini Kamal, F. (Gothenburg); Novin, K. (Tehran)